11,750 Shares in NeuroPace, Inc. (NASDAQ:NPCE) Bought by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. purchased a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,750 shares of the company’s stock, valued at approximately $155,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new position in NeuroPace during the 1st quarter worth $621,000. Vanguard Group Inc. grew its holdings in NeuroPace by 18.3% during the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock worth $6,450,000 after acquiring an additional 75,512 shares in the last quarter. Kent Lake Capital LLC grew its holdings in NeuroPace by 16.8% during the 4th quarter. Kent Lake Capital LLC now owns 670,946 shares of the company’s stock worth $6,917,000 after acquiring an additional 96,529 shares in the last quarter. Finally, Citigroup Inc. acquired a new position in NeuroPace during the 3rd quarter worth $29,000. 78.83% of the stock is owned by institutional investors and hedge funds.

NeuroPace Stock Performance

Shares of NASDAQ NPCE traded down $0.31 during midday trading on Monday, hitting $7.65. The company’s stock had a trading volume of 64,041 shares, compared to its average volume of 113,908. NeuroPace, Inc. has a 1-year low of $3.91 and a 1-year high of $18.15. The firm’s fifty day moving average price is $7.17 and its 200-day moving average price is $11.60. The company has a debt-to-equity ratio of 4.05, a quick ratio of 5.56 and a current ratio of 6.43. The firm has a market cap of $220.09 million, a P/E ratio of -6.43 and a beta of 1.80.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). The business had revenue of $18.12 million during the quarter, compared to analyst estimates of $18.12 million. NeuroPace had a negative net margin of 45.61% and a negative return on equity of 173.62%. On average, sell-side analysts forecast that NeuroPace, Inc. will post -1.14 EPS for the current fiscal year.

Analysts Set New Price Targets

NPCE has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 price objective on shares of NeuroPace in a report on Thursday, May 9th. Morgan Stanley decreased their price target on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, major shareholder Orbimed Advisors Llc sold 1,781 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $14.06, for a total transaction of $25,040.86. Following the completion of the transaction, the insider now directly owns 3,435,541 shares of the company’s stock, valued at approximately $48,303,706.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 22,145 shares of company stock valued at $310,591 in the last ninety days. Company insiders own 22.20% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.